{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:48:59Z","timestamp":1790077739696,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.bulcan.2016.02.001","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T00:53:54Z","timestamp":1457484834000},"page":"478-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibiteurs de tyrosine kinase et grossesse\u00a0: quels risques pour le f\u0153tus\u00a0?"],"prefix":"10.1016","volume":"103","author":[{"given":"C\u00e9cile","family":"Jovelet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Broutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Paci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2016.02.001_bib0300","first-page":"1","article-title":"Death in the United States, 2007","volume":"26","author":"Mini\u00f1o","year":"2009","journal-title":"NCHS Data Brief"},{"issue":"5","key":"10.1016\/j.bulcan.2016.02.001_bib0305","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s10269-013-2282-x","article-title":"Structuration nationale pour la prise en charge des cancers en cours de grossesse\u00a0: r\u00e9seau CALG","volume":"15","author":"Rouzier","year":"2013","journal-title":"Oncologie"},{"key":"10.1016\/j.bulcan.2016.02.001_bib0310","unstructured":"Insee - Population - Un premier enfant \u00e0 28\u00a0ans\u00a0\u00bb. Disponible sur\u00a0: http:\/\/www.insee.fr\/fr\/themes\/document.asp?ref_id=ip1419. [En ligne. Consult\u00e9 le\u00a0: 21-janv-2016]"},{"issue":"9815","key":"10.1016\/j.bulcan.2016.02.001_bib0315","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0140-6736(11)61814-X","article-title":"Cancer in pregnancy: a challenging conflict of interest","volume":"379","author":"Morice","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2016.02.001_bib0320","unstructured":"\u00ab\u00a0Prise en charge des cancers du sein en cours de grossesse (CNGOF)\u00a0\u00bb, Sante-Medecine. Disponible sur\u00a0: http:\/\/sante-medecine.commentcamarche.net\/contents\/958-prise-encharge-des-cancers-du-sein-en-cours-de-grossesse-cngof. [En ligne. Consult\u00e9 le\u00a0: 22-juin-2015]."},{"issue":"4","key":"10.1016\/j.bulcan.2016.02.001_bib0325","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/annonc\/mdm460","article-title":"Emerging therapeutic options for breast cancer chemotherapy during pregnancy","volume":"19","author":"Mir","year":"2008","journal-title":"Ann Oncol ESMO"},{"issue":"4","key":"10.1016\/j.bulcan.2016.02.001_bib0330","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000341820","article-title":"Taxanes during pregnancy: probably safe, but still to be optimized","volume":"83","author":"Berveiller et","year":"2012","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.bulcan.2016.02.001_bib0335","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/IGC.0000000000000062","article-title":"Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting","volume":"24","author":"Amant","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.bulcan.2016.02.001_bib0340","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(12)70331-5","article-title":"Increased evidence for use of chemotherapy in pregnancy","volume":"13","author":"Mir et","year":"2012","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2016.02.001_bib0345","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.ejca.2010.09.010","article-title":"Breast cancer in pregnancy: recommendations of an international consensus meeting","volume":"46","author":"Amant","year":"2010","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2016.02.001_bib0350","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0928-0987(99)00031-7","article-title":"Controlling drug delivery across the placenta","volume":"8","author":"Audus","year":"1999","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.bulcan.2016.02.001_bib0355","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2515\/therapie\/2014002","article-title":"Placental transfer of drugs","volume":"69","author":"Evain-Brion","year":"2014","journal-title":"Therapie"},{"issue":"9","key":"10.1016\/j.bulcan.2016.02.001_bib0360","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1471-0528.1984.tb03700.x","article-title":"Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs","volume":"91","author":"Krauer","year":"1984","journal-title":"Br J Obstet Gynaecol"},{"issue":"11","key":"10.1016\/j.bulcan.2016.02.001_bib0365","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1440-1681.1997.tb02707.x","article-title":"Drug disposition in mother and foetus","volume":"24","author":"Morgan","year":"1997","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"11","key":"10.1016\/j.bulcan.2016.02.001_bib0370","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1111\/j.1447-0756.2011.01591.x","article-title":"Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy","volume":"37","author":"Eskander","year":"2011","journal-title":"J Obstet Gynaecol Res"},{"issue":"6","key":"10.1016\/j.bulcan.2016.02.001_bib0375","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/10428190310001645195","article-title":"Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib","volume":"45","author":"Heartin","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.bulcan.2016.02.001_bib0380","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.leukres.2005.01.009","article-title":"Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission","volume":"29","author":"Ali","year":"2005","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.bulcan.2016.02.001_bib0385","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/10428190500399029","article-title":"Successful outcome of pregnancy in a patient with chronic myelogenous leukemia exposed to imatinib during the first trimester","volume":"47","author":"Suppiah","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.bulcan.2016.02.001_bib0390","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3324\/haematol.10935","article-title":"Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib","volume":"92","author":"Garderet","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bulcan.2016.02.001_bib0395","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5507\/bp.2008.019","article-title":"Successful childbirth in a patient with chronic myelogenous leukemia treated with imatinib mesylate during early pregnancy","volume":"152","author":"Skoumalova","year":"2008","journal-title":"Biomed Pap Med Fac Univ Palack\u00fd Olomouc Czechoslov"},{"issue":"6","key":"10.1016\/j.bulcan.2016.02.001_bib0400","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.leukres.2008.09.012","article-title":"Persistence of molecular remission throughout pregnancy in CML after imatinib","volume":"33","author":"Sor\u00e0","year":"2009","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.bulcan.2016.02.001_bib0405","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.leukres.2008.08.002","article-title":"Is imatinib safe during pregnancy?","volume":"33","author":"Dolai","year":"2009","journal-title":"Leuk Res"},{"issue":"16","key":"10.1016\/j.bulcan.2016.02.001_bib0410","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2169\/internalmedicine.48.2084","article-title":"Successful pregnancy in a patient with chronic myeloid leukemia under treatment with imatinib","volume":"48","author":"Tsuzuki","year":"2009","journal-title":"Intern Med Tokyo Jpn"},{"issue":"2","key":"10.1016\/j.bulcan.2016.02.001_bib0415","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/0971-5851.89795","article-title":"An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib","volume":"32","author":"Martin","year":"2011","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2016.02.001_bib0420","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00404-007-0547-6","article-title":"Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report","volume":"278","author":"Buyukbayrak","year":"2008","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"10.1016\/j.bulcan.2016.02.001_bib0425","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00404-008-0861-7","article-title":"Imatinib use during pregnancy and breast feeding: a case report and review of the literature","volume":"280","author":"Ali","year":"2009","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"10.1016\/j.bulcan.2016.02.001_bib0430","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-0609.2005.00420.x","article-title":"Imatinib in pregnancy","volume":"74","author":"AlKindi","year":"2005","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.bulcan.2016.02.001_bib0435","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1093\/annonc\/mdi398","article-title":"Pregnancy outcome of two patients treated with imatinib","volume":"16","author":"Prabhash","year":"2005","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2016.02.001_bib0440","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1080\/10428190701658751","article-title":"Pregnancy in patients with chronic myeloid leukemia treated with imatinib","volume":"48","author":"Yilmaz","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.bulcan.2016.02.001_bib0445","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12029-012-9464-4","article-title":"Pregnancy with metastatic gastrointestinal stromal tumor (GIST) on imatinib chemotherapy: an oncologist's nightmare and obstetrician's dilemma","volume":"44","author":"Goel","year":"2013","journal-title":"J Gastrointest Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2016.02.001_bib0450","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1532\/IJH97.A20610","article-title":"Pregnancies in patients with chronic myeloid leukemia in the era of imatinib","volume":"84","author":"Koh et","year":"2006","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.bulcan.2016.02.001_bib0455","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/annonc\/mdj065","article-title":"Pregnancy on imatinib: fatal outcome with meningocele","volume":"17","author":"Choudhary","year":"2006","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2016.02.001_bib0460","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5505\/tjh.2012.82542","article-title":"Imatinib use in pregnancy","volume":"29","author":"Webb et","year":"2012","journal-title":"Turk J Haematol"},{"issue":"7","key":"10.1016\/j.bulcan.2016.02.001_bib0465","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2016.02.001_bib0470","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2016.02.001_bib0475","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11845-014-1084-5","article-title":"Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy","volume":"184","author":"Mukhopadhyay","year":"2015","journal-title":"Ir J Med Sci"},{"issue":"9","key":"10.1016\/j.bulcan.2016.02.001_bib0480","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3109\/10428194.2013.866662","article-title":"Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country","volume":"55","author":"Iqbal","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2016.02.001_bib0485","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02413-14","article-title":"Pregnancy outcome after first trimester exposure to fluoroquinolones: an observational cohort study","author":"Padberg","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bulcan.2016.02.001_bib0490","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007223.pub3","article-title":"Medical treatments for incomplete miscarriage","volume":"3","author":"Neilson","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bulcan.2016.02.001_bib0495","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-90-481-9485-8_20","article-title":"The prevalence of congenital anomalies in Europe","volume":"686","author":"Dolk","year":"2010","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"10.1016\/j.bulcan.2016.02.001_bib0500","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3109\/14767058.2013.847420","article-title":"Distribution of congenital anomalies in a neonatal intensive care unit in Turkey","volume":"27","author":"Dursun","year":"2014","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"3","key":"10.1016\/j.bulcan.2016.02.001_bib0505","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/AOG.0b013e31819e9ee2","article-title":"ACOG Practice Bulletin No. 102: management of stillbirth","volume":"113","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bulcan.2016.02.001_bib0510","doi-asserted-by":"crossref","first-page":"136252","DOI":"10.1155\/2010\/136252","article-title":"Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy","volume":"2010","author":"Conchon","year":"2010","journal-title":"Adv Hematol"},{"issue":"9","key":"10.1016\/j.bulcan.2016.02.001_bib0515","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3109\/10428194.2010.497982","article-title":"Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib","volume":"51","author":"Kroll","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bulcan.2016.02.001_bib0520","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.05.2010.2975","article-title":"Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester","volume":"2010","author":"Bayraktar","year":"2010","journal-title":"BMJ Case Rep"},{"issue":"7","key":"10.1016\/j.bulcan.2016.02.001_bib0525","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/CAD.0b013e328352a8fe","article-title":"A dramatic fetal outcome following transplacental transfer of dasatinib","volume":"23","author":"Berveiller","year":"2012","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.bulcan.2016.02.001_bib0530","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.lungcan.2007.10.025","article-title":"Erlotinib administration for advanced non-small cell lung cancer during the first 2\u00a0months of unrecognized pregnancy","volume":"60","author":"Zambelli","year":"2008","journal-title":"Lung Cancer Amst Neth"},{"issue":"2","key":"10.1016\/j.bulcan.2016.02.001_bib0535","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.lungcan.2011.08.008","article-title":"Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure","volume":"74","author":"Lee","year":"2011","journal-title":"Lung Cancer Amst Neth"},{"issue":"2","key":"10.1016\/j.bulcan.2016.02.001_bib0540","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.lungcan.2012.03.026","article-title":"Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma","volume":"77","author":"Rivas","year":"2012","journal-title":"Lung Cancer Amst Neth"},{"issue":"3","key":"10.1016\/j.bulcan.2016.02.001_bib0545","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.lungcan.2014.06.003","article-title":"Efficacy and safety of gefitinib during pregnancy: case report and literature review","volume":"85","author":"Gil","year":"2014","journal-title":"Lung Cancer Amst Neth"},{"issue":"4","key":"10.1016\/j.bulcan.2016.02.001_bib0550","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3816\/CBC.2006.n.048","article-title":"Delivery of a healthy baby after first-trimester maternal exposure to lapatinib","volume":"7","author":"Kelly","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.bulcan.2016.02.001_bib0555","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1756-8722-2-42","article-title":"Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study","volume":"2","author":"Conchon","year":"2009","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2016.02.001_bib0560","doi-asserted-by":"crossref","first-page":"514.e1","DOI":"10.1016\/j.ajog.2012.10.007","article-title":"Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model","volume":"207","author":"Berveiller","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bulcan.2016.02.001_bib0565","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdv172","article-title":"Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model","author":"Jovelet","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2016.02.001_bib0570","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10269-013-2278-6","article-title":"Quels traitements anticanc\u00e9reux pendant la grossesse\u00a0?","volume":"15","author":"Berveiller","year":"2013","journal-title":"Oncologie"},{"issue":"10","key":"10.1016\/j.bulcan.2016.02.001_bib0575","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdu376","article-title":"Drug selection and dosing in pregnant cancer patients: insights from clinical pharmacokinetics","volume":"25","author":"Berveiller","year":"2014","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2016.02.001_bib0580","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jamaoncol.2015.2413","article-title":"Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients","volume":"1","author":"Loibl","year":"2015","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2016.02.001_bib0585","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/AOG.0b013e31826c32d9","article-title":"Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy","volume":"120","author":"Cardonick","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.bulcan.2016.02.001_bib0295","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.placenta.2014.11.001","article-title":"Drug transporter expression during in vitro differentiation of first-trimester and term human villous trophoblasts","volume":"36","author":"Berveiller","year":"2015","journal-title":"Placenta"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455116000606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455116000606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T13:28:14Z","timestamp":1536931694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455116000606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0007455116000606"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2016.02.001","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibiteurs de tyrosine kinase et grossesse\u00a0: quels risques pour le f\u0153tus\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2016.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}